Browsing by Author "Hessol, NA"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- ItemOpen AccessHIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials(BioMed Central Ltd, 2012) Volk, JE; Hessol, NA; Gray, GE; Kublin, JG; Churchyard, G; Mlisana, K; Nchabeleng, M; Buchbinder, SP; Bekker, LWorldwide, many adolescents, especially women, acquire HIV before age 18. Yet to date, no HIV vaccine trials have enrolled adolescents. Reasons for excluding adolescents from these trials include regulations protecting vulnerable subjects and concerns regarding informed consent, social harms, adverse events, and loss to follow-up.